Revenio Group Corporation’s January-March 2024 Interim report will be published on Thursday, April 25, 2024, approximately at 09.00 a.m. (EEST). An audiocast and teleconference call for analysts and investors will be held in English at 3.00 p.m. (EEST) on the same day.

Interim report Q1 2024

## Welcome to Revenio's investor website


Revenio is a leading company in the global market for ophthalmological devices and software solutions. Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand. iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for the diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD).



![](https://storage.googleapis.com/ir-pages-assets-fi/Revenio/elise-zimmerman-ndpRohZL6bE-unsplash.jpg)

### Outlook and guidance

See our guidance

![](https://storage.googleapis.com/inderes-ir-pages-dev-assets/reveniogroup/edi-libedinsky-1bhp9zBPHVE-unsplash.jpg)

### Next event

Annual General Meeting 2024 on April 4, 2024

Key figures

<h2 style="color:white" color:"white">Popular links</h2>

![](https://storage.googleapis.com/ir-pages-assets-fi/Revenio/Robin-Pulkkinen.jpg)

### Investor contacts

CFO Robin Pulkkinen robin.pulkkinen(at)revenio.fi

Thank you for your answers. We will do our best to develop our operations on the basis of this feedback.

Interim report Q1 2024

Welcome to Revenio's investor website

Outlook and guidance

Next event

Key figures

{{stockPrice}} EUR

{{stockPricePercentageChange}}

{{stockPriceLatestDate}}

96.6

MEUR

2023

27.3

%

2023

Releases

Latest video

Popular links

Investor contacts